Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCENT-07: sacituzumab govitecan versus physician's choice chemotherapy in HR-positive/HER2-negative advanced breast cancer
MOH_2023-07-17_012821Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- May 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of sacituzumab govitecan, sponsored by Gilead Sciences. Started May 2023; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
Beyond the preview
Go deeper on MOH_2023-07-17_012821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-07-17_012821.